2 items2 sources1 stocks
SEC EDGAR-Oct 19, 12:00 PM
Disc Medicine, 8-K (7.01, 8.01, 9.01): Regulation FD disclosure
Disc Medicine reported that bitopertin met all primary and secondary endpoints in its 183-patient Phase 3 APOLLO trial for EPP, including a 41.4% PPIX reduction and 12.2 additional monthly hours in light without pain versus placebo, and plans an NDA resubmission by end-2026.
Yahoo Finance / Benzinga-Oct 18, 12:10 PM
Disc Medicine (IRON) Stock Still Looks Pricey As Book Value Lags Expectations - Yahoo Finance
Disc Medicine (IRON) Stock Still Looks Pricey As Book Value Lags Expectations - Yahoo Finance（摘要待生成）